DE602006004694D1 - Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen - Google Patents

Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen

Info

Publication number
DE602006004694D1
DE602006004694D1 DE602006004694T DE602006004694T DE602006004694D1 DE 602006004694 D1 DE602006004694 D1 DE 602006004694D1 DE 602006004694 T DE602006004694 T DE 602006004694T DE 602006004694 T DE602006004694 T DE 602006004694T DE 602006004694 D1 DE602006004694 D1 DE 602006004694D1
Authority
DE
Germany
Prior art keywords
pharmaceutical
preparation
wet granulation
granulation method
aripiprazole compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006004694T
Other languages
English (en)
Inventor
Julia Hrakovsky
Ruth Tenengauzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36637023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006004694(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE602006004694D1 publication Critical patent/DE602006004694D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006004694T 2006-01-05 2006-03-14 Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen Active DE602006004694D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75670806P 2006-01-05 2006-01-05

Publications (1)

Publication Number Publication Date
DE602006004694D1 true DE602006004694D1 (de) 2009-02-26

Family

ID=36637023

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006004694T Active DE602006004694D1 (de) 2006-01-05 2006-03-14 Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen

Country Status (13)

Country Link
US (1) US8865722B2 (de)
EP (2) EP1808164B2 (de)
JP (1) JP4875001B2 (de)
CN (1) CN101351192A (de)
AT (1) ATE419837T1 (de)
CA (1) CA2627693A1 (de)
DE (1) DE602006004694D1 (de)
DK (1) DK1808164T3 (de)
ES (1) ES2318693T5 (de)
IL (1) IL190916A0 (de)
PL (1) PL1808164T3 (de)
PT (1) PT1808164E (de)
WO (1) WO2007081366A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
TR200604349A2 (tr) * 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2010079506A2 (en) 2008-06-23 2010-07-15 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of aripiprazole
WO2011032882A1 (en) 2009-09-15 2011-03-24 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
CN102106826B (zh) * 2009-12-29 2013-06-05 上海中西制药有限公司 一种阿立哌唑固体制剂及其制备方法
ES2533075T3 (es) * 2010-04-30 2015-04-07 Bristol-Myers Squibb Company Composiciones farmacéuticas que comprenden N-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4-etoxi-1-(4-fluorofenil)-2-oxo-1,2-dihidropiridin-3-carboxamida
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
US9717707B2 (en) * 2011-12-08 2017-08-01 Hexal Ag Pharmaceutical statin composition
WO2014104989A1 (en) * 2011-12-27 2014-07-03 Mahmut Bilgic Pharmaceutical compositions comprising aripiprazole
WO2013100878A1 (en) * 2011-12-27 2013-07-04 Mahmut Bilgic Pharmaceutical formulations comprising aripiprazole
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
EP3187173A1 (de) * 2013-04-30 2017-07-05 Otsuka Pharmaceutical Co., Ltd. Orales festes präparat mit aripiprazol und verfahren zur herstellung eines oralen festen präparats mit aripiprazol
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
GR1008442B (el) * 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
EP3002005A1 (de) * 2014-09-30 2016-04-06 Molkerei Meggle Wasserburg GmbH & Co. Kg Direktkomprimierter Hilfsstoff auf Basis von Lactose, Cellulose und Stärke
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71629C2 (en) * 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
WO2003030868A1 (en) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
TWI324074B (en) 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
JP2003238393A (ja) * 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
WO2004083183A1 (en) 2003-03-21 2004-09-30 Hetero Drugs Limited Novel crystalline forms of aripiprazole
WO2004106322A2 (en) 2003-04-25 2004-12-09 Cadila Healthcare Limited Polymorphs of aripiprazole
US20050158383A1 (en) * 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
KR100931784B1 (ko) 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
WO2005058835A2 (en) 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
ES2332920T3 (es) 2004-01-20 2010-02-15 Novartis Ag Proceso y formulacion de compresion directa.
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
CN101111481A (zh) 2004-11-18 2008-01-23 斯索恩有限公司 制备结晶阿立哌唑的方法
EP1812396A1 (de) 2004-11-18 2007-08-01 Synthon B.V. Kristalline aripiprazolsolvate
EP1686117A1 (de) 2005-01-27 2006-08-02 Sandoz AG Polymorph und Solvate von Aripiprazol
CA2600542A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
EP1879865A1 (de) 2005-04-15 2008-01-23 Medichem S.A. Synthesen und herstellungen von polymorphen aus kristallinem aripiprazol
JP2008540644A (ja) 2005-07-15 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド 新規粒質化方法及びそれから生成される粒質物
US20070014853A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070014864A1 (en) 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
US20070014854A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007073389A1 (en) 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US20070148245A1 (en) 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
JP2008537540A (ja) 2005-12-22 2008-09-18 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾールの粒径を小さくする方法
US20090054455A1 (en) 2006-02-03 2009-02-26 Dr. Reddy's Laboratories Ltd. Aripiprazole co-crystals
EP1880714A1 (de) 2006-07-20 2008-01-23 Helm AG Amorphes Aripiprazol und Verfahren zu dessen Herstellung

Also Published As

Publication number Publication date
ES2318693T3 (es) 2009-05-01
EP1808164A1 (de) 2007-07-18
PL1808164T3 (pl) 2009-06-30
US20070154544A1 (en) 2007-07-05
EP1808164B2 (de) 2018-07-04
DK1808164T3 (da) 2009-04-20
ES2318693T5 (es) 2018-10-04
ATE419837T1 (de) 2009-01-15
PT1808164E (pt) 2009-03-17
JP4875001B2 (ja) 2012-02-15
CN101351192A (zh) 2009-01-21
WO2007081366A1 (en) 2007-07-19
US8865722B2 (en) 2014-10-21
EP2036545A1 (de) 2009-03-18
IL190916A0 (en) 2008-11-03
JP2008531737A (ja) 2008-08-14
EP1808164B1 (de) 2009-01-07
CA2627693A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
DE602006004694D1 (de) Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
NL2000690A1 (nl) Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine.
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
ATE429906T1 (de) Trockene aripiprazolformulierungen
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
BRPI0810646A2 (pt) " compostos farmacêuticos ".
BRPI0715712A2 (pt) Composição farmacêutica
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0719393A2 (pt) Composição farmacêutica
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0809661A2 (pt) Composição farmacêutica estabilizada contendo pregabalina
BRPI0720234A2 (pt) Composição farmacêutica
IL194961A0 (en) Compounds a-r-x for the manufacture of pharmaceutical preparations
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
BRPI0913709A2 (pt) "formulação farmacêutica"
DK2216039T3 (da) Farmaceutiske sammensætninger til behandling af angst
DE602005007319D1 (de) Zubereitung zur kontinuierlichen Arzneimittelfreisetzung Chitosan enthaltend
DE602006017753D1 (de) Vorrichtung zur herstellung von pharmazeutischen produkten
BRPI0815893A2 (pt) formulação farmacêutica de liberação prolongada.
BRPI0719398A2 (pt) Composição farmacêutica.
ES1059240Y (es) Protector de mucosa oral para aplicaciones ortodoncicas.

Legal Events

Date Code Title Description
8363 Opposition against the patent